Analysis of PI3K pathway components in human cancers

被引:21
作者
Daragmeh, Jamila [1 ]
Barriah, Waseim [2 ]
Saad, Bashar [1 ,2 ]
Zaid, Hilal [1 ,2 ]
机构
[1] Arab Amer Univ Jenin, Fac Arts & Sci, POB 240, Jenin 11184, Palestine
[2] Al Qasemi Acad, Coll Educ, Qasemi Res Ctr, IL-30100 Baqa El Gharbia, Israel
关键词
cancer; tumorigenesis; Human Protein Atlas; PI3K; AKT; TSC1; EGFR; PTEN; PHOSPHOINOSITIDE 3-KINASE PATHWAY; PI3K/AKT/MTOR PATHWAY; CELL; APOPTOSIS; KINASE; GENE; INHIBITION; RATIONALE; MUTATIONS;
D O I
10.3892/ol.2016.4309
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent advances in genomics, proteomics, cell biology and biochemistry of tumors have revealed new pathways that are aberrantly activated in numerous cancer types. However, the enormous amount of data available in this field may mislead scientists in focused research. As cancer cell growth and progression is often dependent upon the phosphoinositide 3-kinase (PI3K)/AKT pathway, there has been extensive research into the proteins implicated in the PI3K pathway. Using data available in the Human Protein Atlas database, the current study investigated the expression of 25 key proteins that are known to be involved with PI3K pathway activation in a distinct group of 20 cancer types. These proteins are AKTIP, ARP1, BAD, GSK3A, GSK3B, MERTK-1, PIK3CA, PRR5, PSTPIP2, PTEN, FOX1, RHEB, RPS6KB1, TSC1, TP53, BCL2, CCND1, WFIKKN2, CREBBP, caspase-9, PTK2, EGFR, FAS, CDKN1A and XIAP. The analysis revealed pronounced expression of specific proteins in distinct cancer tissues, which may have the potential to serve as targets for treatments and provide insights into the molecular basis of cancer.
引用
收藏
页码:2913 / 2918
页数:6
相关论文
共 43 条
[1]   Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics [J].
Akinleye, Akintunde ;
Avvaru, Parthu ;
Furqan, Muhammad ;
Song, Yongping ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[2]  
[Anonymous], BIOMED RES INT
[3]   Coordinate PI3K pathway and Bcl-2 family disruption in AML [J].
Bose, Prithviraj ;
Rahmani, Mohamed ;
Grant, Steven .
ONCOTARGET, 2012, 3 (12) :1499-1500
[4]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[5]   Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook [J].
Cho, Daniel C. .
BIODRUGS, 2014, 28 (04) :373-381
[6]   The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival [J].
Cooray, S .
JOURNAL OF GENERAL VIROLOGY, 2004, 85 :1065-1076
[7]   Molecular Pathways: MERTK Signaling in Cancer [J].
Cummings, Christopher T. ;
DeRyckere, Deborah ;
Earp, H. Shelton ;
Graham, Douglas K. .
CLINICAL CANCER RESEARCH, 2013, 19 (19) :5275-5280
[8]   Regulation of TORC1 in Response to Amino Acid Starvation via Lysosomal Recruitment of TSC2 [J].
Demetriades, Constantinos ;
Doumpas, Nikolaos ;
Teleman, Aurelio A. .
CELL, 2014, 156 (04) :786-799
[9]   Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin [J].
Du, Wa ;
Gerald, Damien ;
Perruzzi, Carole A. ;
Rodriguez-Waitkus, Paul ;
Enayati, Ladan ;
Krishnan, Bhuvaneswari ;
Edmonds, Joseph ;
Hochman, Marcelo L. ;
Lev, Dina C. ;
Phung, Thuy L. .
LABORATORY INVESTIGATION, 2013, 93 (10) :1115-1127
[10]   PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12 [J].
Gan, Xiaoqing ;
Wang, Jiyong ;
Wang, Chen ;
Sommer, Eeva ;
Kozasa, Tohru ;
Srinivasula, Srinivasa ;
Alessi, Dario ;
Offermanns, Stefan ;
Simon, Melvin I. ;
Wu, Dianqing .
NATURE CELL BIOLOGY, 2012, 14 (07) :686-696